uniQure N.V. Inventory Write-down
uniQure N.V. (QURE) reported Inventory Write-down of $6.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2025-11-10
- uniQure N.V. inventory write-down for the quarter ending 2024-12-31 was $3.00K, a 99.81% decline year-over-year.
- uniQure N.V. inventory write-down for the quarter ending 2024-09-30 was $500.00K.
- uniQure N.V. inventory write-down for the quarter ending 2024-06-30 was $4.10M.
- uniQure N.V. inventory write-down for the quarter ending 2024-03-31 was $1.80M.
- uniQure N.V. inventory write-down for fiscal 2024 was $6.30M, a 293.75% increase from fiscal 2023.
- uniQure N.V. inventory write-down for fiscal 2023 was $1.60M.
- uniQure N.V. inventory write-down for fiscal 2022 was $0.00.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $503.00K derived: sum of 2 quarters · filed 2025-02-27 | $4.60M derived: sum of 3 quarters · filed 2025-02-27 | $6.30M 10-K · filed 2025-02-27 |
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-05 | $4.60M derived: sum of 2 quarters · filed 2024-11-05 | $6.30M 10-Q · filed 2025-11-10 | $8.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $4.10M 10-Q · filed 2024-08-01 | $5.84M 10-Q · filed 2025-07-29 | $7.50M derived: sum of 3 quarters · filed 2025-02-27 | $7.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $1.80M 10-Q · filed 2024-05-07 | $3.40M derived: sum of 2 quarters · filed 2025-02-27 | $3.40M derived: sum of 3 quarters · filed 2025-02-27 | $3.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.60M derived: sum of 2 quarters · filed 2025-02-27 | $1.60M derived: sum of 3 quarters · filed 2025-02-27 | $1.60M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |